Determining Prognosis for Patients with Differentiated Thyroid Cancer

Francis Worden, MD, discusses the prognosis for patients with differentiated thyroid cancer, distinguishing between those who can be put on close surveillance and those who require immediate treatment, while the panel weighs in on best practices for predicting and anticipating disease-related obstructions prior to the onset of symptoms.

EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends

EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer

Now Viewing

EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer

EP: 4.Predisposition for Patients Developing DTC: Age and Gender

EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management

EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

EP: 7.The Importance of Thyroidectomy in DTC Patient Care

EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression

EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned

EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy

EP: 12.Exploring Real-World Evidence Presented at ATA 2023

EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC

EP: 14.Toxicity Profiles for DTC Guidelines Therapies

EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment

EP: 16.Neoadjuvant Approach in RAI-R-DTC

EP: 17.Phase 2 ATLEP Trial Results

EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights

Related Videos

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment